Grace Capital’s Exact Sciences EXAS Stock Holding History

Grace Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-507	Closed	-$67K	–	171
2021 Q1	$67K	Buy	+507	New	+$69.4K	0.04%	201

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Grace Capital's EXAS Position: Q2 2021 in Review

Grace Capital sold out of Exact Sciences (EXAS) in Q2 2021, closing a stake of 507 shares — an estimated $67K sold.

Grace Capital first reported a position in EXAS in Q1 2021 and held it in 1 quarter. The position peaked at $67K in Q1 2021. 622 funds tracked by Wall St. Rank hold EXAS as of Q2 2021.

Grace Capital reported no remaining Exact Sciences position as of Q2 2021 after selling out during the quarter.
Grace Capital sold 507 Exact Sciences shares in Q2 2021, an estimated $67K.
Grace Capital first reported a position in Exact Sciences in Q1 2021 and held it in 1 quarter.
Grace Capital's Exact Sciences position peaked at $67K in Q1 2021.
622 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2021.

Based on Grace Capital's 13F filing for Q2 2021, filed 11 Aug 2021.